Product Code: SR112024A2188
Abstract
The global transfection technologies market size reached US$ 1,172.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 2,275.3 Million by 2032, exhibiting a growth rate (CAGR) of 7.4% during 2024-2032.
Transfection technology refers to the process of artificially introducing nucleic acid, such as Deoxyribonucleic Acid (DNA), Ribonucleic Acid (RNA) and oligonucleotides, into the cells. It is introduced using various physical, chemical and biological methods, which can assist in modifying certain properties of the cell. It involves various methods, including cotransfection, electroporation, cationic lipid transfection and in-vivo transfection. This process is commonly used for various genomic studies that include gene expression, screening, RNA interference and Vivo research, along with the bioproduction of viruses and proteins.
The increasing prevalence of cancer and various chronic lifestyle diseases is one of the key factors driving the growth of the market. Furthermore, widespread adoption of reagent-based methods is also providing a boost to the market growth. In comparison to the traditionally used techniques, reagent-based transfection is less complicated to administer and more cost-effective. In line with this, instrument-based methods, such as biolistic technology, microinjection and laserfection, are also gaining immense traction across the globe. Various technological advancements in cell research and therapeutic discovery are acting as another major growth-inducing factor. In line with this, research in gene transfer is majorly performed under in-vivo conditions for the development of novel therapeutic drugs and various other applications. Other factors, including increasing investments by both government and private organizations to develop large scale transfection facilities, along with extensive research and development (R&D) activities in the field of protein therapeutics, are projected to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global transfection technologies market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, application, transfection method, technology and end-user.
Breakup by Product Type:
Reagent
Instrument
Others
Breakup by Application:
Therapeutic Delivery
Bio-Medical Research
Protein Production
Others
Breakup by Transfection Method:
Lipofection
Eletroporation
Nucleofection
Cotransfection
Cationic Lipid Transfection
In-Vivo Transfection
Others
Breakup by Technology:
Physical Transfection
Biochemical Based Transfection
Viral-Vector Based Transfection
Breakup by End-User:
Research Centers and Academic Institutes
Hospitals and Clinics
Pharmaceutical and Biotechnology Companies
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., Bio-RAD Laboratories Inc., Lonza Group AG, Maxcyte Inc., Mirus Bio LLC, Polyplus Transfection, Promega Corporation, Roche Holding AG, Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc., etc.
Key Questions Answered in This Report
- 1. What was the size of the global transfection technologies market in 2023?
- 2. What is the expected growth rate of the global transfection technologies market during 2024-2032?
- 3. What are the key factors driving the global transfection technologies market?
- 4. What has been the impact of COVID-19 on the global transfection technologies market?
- 5. What is the breakup of the global transfection technologies market based on the product type?
- 6. What is the breakup of the global transfection technologies market based on the application?
- 7. What is the breakup of the global transfection technologies market based on the transfection method?
- 8. What is the breakup of the global transfection technologies market based on the technology?
- 9. What are the key regions in the global transfection technologies market?
- 10. Who are the key players/companies in the global transfection technologies market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Transfection Technologies Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product Type
- 6.1 Reagent
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Instrument
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Others
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Application
- 7.1 Therapeutic Delivery
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Bio-Medical Research
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Protein Production
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Transfection Method
- 8.1 Lipofection
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Eletroporation
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Nucleofection
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Cotransfection
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Cationic Lipid Transfection
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
- 8.6 In-Vivo Transfection
- 8.6.1 Market Trends
- 8.6.2 Market Forecast
- 8.7 Others
- 8.7.1 Market Trends
- 8.7.2 Market Forecast
9 Market Breakup by Technology
- 9.1 Physical Transfection
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Biochemical Based Transfection
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Viral-Vector Based Transfection
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by End-User
- 10.1 Research Centers and Academic Institutes
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
- 10.2 Hospitals and Clinics
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
- 10.3 Pharmaceutical and Biotechnology Companies
- 10.3.1 Market Trends
- 10.3.2 Market Forecast
- 10.4 Others
- 10.4.1 Market Trends
- 10.4.2 Market Forecast
11 Market Breakup by Region
- 11.1 North America
- 11.1.1 United States
- 11.1.1.1 Market Trends
- 11.1.1.2 Market Forecast
- 11.1.2 Canada
- 11.1.2.1 Market Trends
- 11.1.2.2 Market Forecast
- 11.2 Asia Pacific
- 11.2.1 China
- 11.2.1.1 Market Trends
- 11.2.1.2 Market Forecast
- 11.2.2 Japan
- 11.2.2.1 Market Trends
- 11.2.2.2 Market Forecast
- 11.2.3 India
- 11.2.3.1 Market Trends
- 11.2.3.2 Market Forecast
- 11.2.4 South Korea
- 11.2.4.1 Market Trends
- 11.2.4.2 Market Forecast
- 11.2.5 Australia
- 11.2.5.1 Market Trends
- 11.2.5.2 Market Forecast
- 11.2.6 Indonesia
- 11.2.6.1 Market Trends
- 11.2.6.2 Market Forecast
- 11.2.7 Others
- 11.2.7.1 Market Trends
- 11.2.7.2 Market Forecast
- 11.3 Europe
- 11.3.1 Germany
- 11.3.1.1 Market Trends
- 11.3.1.2 Market Forecast
- 11.3.2 France
- 11.3.2.1 Market Trends
- 11.3.2.2 Market Forecast
- 11.3.3 United Kingdom
- 11.3.3.1 Market Trends
- 11.3.3.2 Market Forecast
- 11.3.4 Italy
- 11.3.4.1 Market Trends
- 11.3.4.2 Market Forecast
- 11.3.5 Spain
- 11.3.5.1 Market Trends
- 11.3.5.2 Market Forecast
- 11.3.6 Russia
- 11.3.6.1 Market Trends
- 11.3.6.2 Market Forecast
- 11.3.7 Others
- 11.3.7.1 Market Trends
- 11.3.7.2 Market Forecast
- 11.4 Latin America
- 11.4.1 Brazil
- 11.4.1.1 Market Trends
- 11.4.1.2 Market Forecast
- 11.4.2 Mexico
- 11.4.2.1 Market Trends
- 11.4.2.2 Market Forecast
- 11.4.3 Others
- 11.4.3.1 Market Trends
- 11.4.3.2 Market Forecast
- 11.5 Middle East and Africa
- 11.5.1 Market Trends
- 11.5.2 Market Breakup by Country
- 11.5.3 Market Forecast
12 SWOT Analysis
- 12.1 Overview
- 12.2 Strengths
- 12.3 Weaknesses
- 12.4 Opportunities
- 12.5 Threats
13 Value Chain Analysis
14 Porters Five Forces Analysis
- 14.1 Overview
- 14.2 Bargaining Power of Buyers
- 14.3 Bargaining Power of Suppliers
- 14.4 Degree of Competition
- 14.5 Threat of New Entrants
- 14.6 Threat of Substitutes
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Agilent Technologies Inc.
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Bio-RAD Laboratories Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Lonza Group AG
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Maxcyte Inc.
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.5 Mirus Bio LLC
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.6 Polyplus Transfection
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.7 Promega Corporation
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.8 Roche Holding AG
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.9 Sigma-Aldrich Corporation
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.10 Thermo Fisher Scientific Inc.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis